Skip to main content
All-In with Chamath, Jason, Sacks & Friedberg

Are Psychedelics the Key to Living Forever? (ft. Bryan Johnson)

37 min episode · 2 min read
·

Episode

37 min

Read time

2 min

Topics

Health & Wellness, Product & Tech Trends, Psychology & Behavior

AI-Generated Summary

Key Takeaways

  • Psychedelic Dosing Protocol: Johnson administered 9mg intramuscular followed by 18mg vaporized 5-MeO-DMT under supervised, quantified conditions — not recreational settings. He argues that most adverse outcomes from psychedelics stem from unknown mushroom strains, unmeasured psilocybin doses, and unsupervised environments, making structured clinical protocols the critical variable separating therapeutic benefit from psychological harm.
  • Default Mode Network Reset: 5-MeO-DMT completely disrupts the default mode network — the brain system responsible for ego, rumination, and self-referential thought. Using Kernel's optical brain interface, Johnson previously documented that psilocybin at 25mg clinical doses visibly scrambled neural traffic patterns, generating new connectivity. He describes 5-MeO-DMT as producing a far more complete shutdown than psilocybin.
  • Psilocybin Metabolic Data: Three 25mg psilocybin doses produced a measurable metabolic reset in Johnson's body, moving his blood glucose from the 99.5th to the 99.9th population percentile — a shift he describes as extremely difficult to achieve through conventional interventions. The protocol also altered his microbiome composition, suggesting systemic effects beyond neurological changes alone.
  • Mitochondrial Transplantation Pipeline: Johnson is pursuing mitochondrial therapy through a phase-two company within weeks. The strategy involves drawing blood from a maternally-related young donor — whose mitochondria are genetically matched — culturing those mitochondria externally, then reintroducing them. He suggests sprint performance testing as a practical biomarker to measure functional improvement beyond standard blood panels.
  • Personalized Organoid Testing: Johnson has converted his own blood cells into induced pluripotent stem cells, then differentiated them into heart, liver, and lung tissue organoids. This system allows candidate drugs and compounds to be tested on his own tissue in a dish before human administration, compressing the trial-and-error timeline and enabling combinatorial dosing experiments without direct personal risk.

What It Covers

Bryan Johnson documents his 5-MeO-DMT experience as a structured longevity experiment, comparing its neurological effects to psilocybin trials he previously conducted. He presents preliminary data on brain rejuvenation, default mode network disruption, and metabolic reset, while discussing upcoming therapies including mitochondrial transplantation and personalized organoids.

Key Questions Answered

  • Psychedelic Dosing Protocol: Johnson administered 9mg intramuscular followed by 18mg vaporized 5-MeO-DMT under supervised, quantified conditions — not recreational settings. He argues that most adverse outcomes from psychedelics stem from unknown mushroom strains, unmeasured psilocybin doses, and unsupervised environments, making structured clinical protocols the critical variable separating therapeutic benefit from psychological harm.
  • Default Mode Network Reset: 5-MeO-DMT completely disrupts the default mode network — the brain system responsible for ego, rumination, and self-referential thought. Using Kernel's optical brain interface, Johnson previously documented that psilocybin at 25mg clinical doses visibly scrambled neural traffic patterns, generating new connectivity. He describes 5-MeO-DMT as producing a far more complete shutdown than psilocybin.
  • Psilocybin Metabolic Data: Three 25mg psilocybin doses produced a measurable metabolic reset in Johnson's body, moving his blood glucose from the 99.5th to the 99.9th population percentile — a shift he describes as extremely difficult to achieve through conventional interventions. The protocol also altered his microbiome composition, suggesting systemic effects beyond neurological changes alone.
  • Mitochondrial Transplantation Pipeline: Johnson is pursuing mitochondrial therapy through a phase-two company within weeks. The strategy involves drawing blood from a maternally-related young donor — whose mitochondria are genetically matched — culturing those mitochondria externally, then reintroducing them. He suggests sprint performance testing as a practical biomarker to measure functional improvement beyond standard blood panels.
  • Personalized Organoid Testing: Johnson has converted his own blood cells into induced pluripotent stem cells, then differentiated them into heart, liver, and lung tissue organoids. This system allows candidate drugs and compounds to be tested on his own tissue in a dish before human administration, compressing the trial-and-error timeline and enabling combinatorial dosing experiments without direct personal risk.

Notable Moment

Johnson describes waking up laughing during a dream two days after his 5-MeO-DMT session — something he could not recall ever doing before. He then looked it up and found that laughing in dreams is documented as a characteristic behavior of children, suggesting a measurable restoration of childlike neural states.

Know someone who'd find this useful?

Episode Transcript

Brian Johnson, thanks for being here. Yeah. It's good to see you. How are you feeling? Maybe just share with us what you did a few days ago and Yeah. I did, a I did five MEO DMT, which is the most powerful psychedelic on the planet. Somewhere between five and ten times more powerful than DMT. And so, yeah, I it's so it's been forty eight hours. I'm still learning how to talk about it. You know what many of the biggest tech CEOs and VCs have in common? They sleep on the pod by Eight Sleep. It's become tech's favorite way to sleep and for good reason. A cover that goes on any mattress, cools it down to 55 degrees, and uses AI to adjust your temperature all night up to 34% more deep sleep. No wearable needed. Go to 8sleep.com slash all in and use code all in for up to $350 off your pod purchase today. Before we get into your experience, why did you choose to do it? Two things. One, mostly as a longevity experiment. So when when we when I started this project five years ago, the the approach we had was go through all the scientific evidence ever published on health and longevity. Try to find the interventions that have the best evidence, for effect size. And we just went down the list from top performing on down. So, of course, you start with, exercise, nutrition, you know, sleep. And you work your way down to things like hyperbaric oxygen therapy and sauna and then rapamycin metformin. And so we never actually had on our radar psychedelics. They were always either an ancient medicine, you know, being used in in ritualistic practices or being pointed at things like depression and anxiety in in certain trials. But it was never understood as a rejuvenation protocol, something that was for antiaging. And so we found a preclinical evidence in mice on psilocybin, we thought, that's interesting. And so we did the world's most studied the most, quantified experiment doing psilocybin, three doses at, twenty five milligrams, of psilocybin. Which are pretty high doses. It's yeah. It's a clinical, dose. Very, very close to a hero dose. And we found that we think it's a a longevity therapy. Let's get to that data in a minute. But then you decided to try five MEO this weekend. Yes. Walk me through the experience because you televised the whole thing. It was live streamed. You looked amazingly calm going into it and going through the process. Walk us through your experience. Yeah. I think, those who have done five MEO would probably relate with me that it feels like an impossible task to explain what it's like. So that caveat said, I'll I'll give it a go. I'm stunned. Absolutely floored. Speechless. You you basically experience raw consciousness and raw intelligence. It's this so whatever when I say these words, take these words that I commit to …

Get the full transcript (7,311 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all All-In with Chamath, Jason, Sacks & Friedberg transcripts →

You just read a 3-minute summary of a 34-minute episode.

Get All-In with Chamath, Jason, Sacks & Friedberg summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

Books, tools, and gear mentioned in this episode

SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.

Gear

  • by Kernel

    Using Kernel's optical brain interface, Johnson previously documented that psilocybin at 25mg clinical doses visibly scrambled neural traffic patterns, generating new connectivity.
  • by Eight Sleep

    Eight Sleep listed as sponsor with url https://8sleep.com/allin

More from All-In with Chamath, Jason, Sacks & Friedberg

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Tech Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into All-In with Chamath, Jason, Sacks & Friedberg.

Every Monday, we deliver AI summaries of the latest episodes from All-In with Chamath, Jason, Sacks & Friedberg and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime